Comment from Maryland Right to Life, Inc.

Summary: Maryland Right to Life, Inc., a pro-life organization, opposes the FDA's proposal to weaken safety protocols and remove Risk Evaluation and Mitigation Strategy (REMs) requirements for mifepristone. They argue that the drug poses significant risks to women and children and that robust safety measures are necessary to prevent substandard care and protect public health.